Cargando…
In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis
[Image: see text] Candidal vulvovaginitis involving multispecies of Candida and epithelium-bound biofilm poses a drug-resistant pharmacotherapeutic challenge. The present study aims for a disease-specific predominant causative organism resolution for the development of a tailored vaginal drug delive...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947946/ https://www.ncbi.nlm.nih.gov/pubmed/36844532 http://dx.doi.org/10.1021/acsomega.2c07718 |
_version_ | 1784892671672713216 |
---|---|
author | Hassan, Nazia Farooq, Uzma Das, Ayan Kumar Sharma, Kalicharan Mirza, Mohd. Aamir Fatima, Suhail Singh, Omana Ansari, Mohammad Javed Ali, Asgar Iqbal, Zeenat |
author_facet | Hassan, Nazia Farooq, Uzma Das, Ayan Kumar Sharma, Kalicharan Mirza, Mohd. Aamir Fatima, Suhail Singh, Omana Ansari, Mohammad Javed Ali, Asgar Iqbal, Zeenat |
author_sort | Hassan, Nazia |
collection | PubMed |
description | [Image: see text] Candidal vulvovaginitis involving multispecies of Candida and epithelium-bound biofilm poses a drug-resistant pharmacotherapeutic challenge. The present study aims for a disease-specific predominant causative organism resolution for the development of a tailored vaginal drug delivery system. The proposed work fabricates a luliconazole-loaded nanostructured lipid carrier-based transvaginal gel for combating Candida albicans biofilm and disease amelioration. The interaction and binding affinity of luliconazole against the proteins of C. albicans and biofilm were assessed using in silico tools. A systematic QbD analysis was followed to prepare the proposed nanogel using a modified melt emulsification–ultrasonication–gelling method. The DoE optimization was logically implemented to ascertain the effect of independent process variables (excipients concentration; sonication time) on dependent formulation responses (particle size; polydispersity index; entrapment efficiency). The optimized formulation was characterized for final product suitability. The surface morphology and dimensions were spherical and ≤300 nm, respectively. The flow behavior of an optimized nanogel (semisolid) was non-Newtonian similar to marketed preparation. The texture pattern of a nanogel was firm, consistent, and cohesive. The release kinetic model followed was Higuchi (nanogel) with a % cumulative drug release of 83.97 ± 0.69% in 48 h. The % cumulative drug permeated across a goat vaginal membrane was found to be 53.148 ± 0.62% in 8 h. The skin-safety profile was examined using a vaginal irritation model (in vivo) and histological assessments. The drug and proposed formulation(s) were checked against the pathogenic strains of C. albicans (vaginal clinical isolates) and in vitro established biofilms. The visualization of biofilms was done under a fluorescence microscope revealing mature, inhibited, and eradicated biofilm structures. |
format | Online Article Text |
id | pubmed-9947946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-99479462023-02-24 In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis Hassan, Nazia Farooq, Uzma Das, Ayan Kumar Sharma, Kalicharan Mirza, Mohd. Aamir Fatima, Suhail Singh, Omana Ansari, Mohammad Javed Ali, Asgar Iqbal, Zeenat ACS Omega [Image: see text] Candidal vulvovaginitis involving multispecies of Candida and epithelium-bound biofilm poses a drug-resistant pharmacotherapeutic challenge. The present study aims for a disease-specific predominant causative organism resolution for the development of a tailored vaginal drug delivery system. The proposed work fabricates a luliconazole-loaded nanostructured lipid carrier-based transvaginal gel for combating Candida albicans biofilm and disease amelioration. The interaction and binding affinity of luliconazole against the proteins of C. albicans and biofilm were assessed using in silico tools. A systematic QbD analysis was followed to prepare the proposed nanogel using a modified melt emulsification–ultrasonication–gelling method. The DoE optimization was logically implemented to ascertain the effect of independent process variables (excipients concentration; sonication time) on dependent formulation responses (particle size; polydispersity index; entrapment efficiency). The optimized formulation was characterized for final product suitability. The surface morphology and dimensions were spherical and ≤300 nm, respectively. The flow behavior of an optimized nanogel (semisolid) was non-Newtonian similar to marketed preparation. The texture pattern of a nanogel was firm, consistent, and cohesive. The release kinetic model followed was Higuchi (nanogel) with a % cumulative drug release of 83.97 ± 0.69% in 48 h. The % cumulative drug permeated across a goat vaginal membrane was found to be 53.148 ± 0.62% in 8 h. The skin-safety profile was examined using a vaginal irritation model (in vivo) and histological assessments. The drug and proposed formulation(s) were checked against the pathogenic strains of C. albicans (vaginal clinical isolates) and in vitro established biofilms. The visualization of biofilms was done under a fluorescence microscope revealing mature, inhibited, and eradicated biofilm structures. American Chemical Society 2023-02-10 /pmc/articles/PMC9947946/ /pubmed/36844532 http://dx.doi.org/10.1021/acsomega.2c07718 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Hassan, Nazia Farooq, Uzma Das, Ayan Kumar Sharma, Kalicharan Mirza, Mohd. Aamir Fatima, Suhail Singh, Omana Ansari, Mohammad Javed Ali, Asgar Iqbal, Zeenat In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis |
title | In Silico Guided
Nanoformulation Strategy for Circumvention
of Candida albicans Biofilm for Effective Therapy
of Candidal Vulvovaginitis |
title_full | In Silico Guided
Nanoformulation Strategy for Circumvention
of Candida albicans Biofilm for Effective Therapy
of Candidal Vulvovaginitis |
title_fullStr | In Silico Guided
Nanoformulation Strategy for Circumvention
of Candida albicans Biofilm for Effective Therapy
of Candidal Vulvovaginitis |
title_full_unstemmed | In Silico Guided
Nanoformulation Strategy for Circumvention
of Candida albicans Biofilm for Effective Therapy
of Candidal Vulvovaginitis |
title_short | In Silico Guided
Nanoformulation Strategy for Circumvention
of Candida albicans Biofilm for Effective Therapy
of Candidal Vulvovaginitis |
title_sort | in silico guided
nanoformulation strategy for circumvention
of candida albicans biofilm for effective therapy
of candidal vulvovaginitis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947946/ https://www.ncbi.nlm.nih.gov/pubmed/36844532 http://dx.doi.org/10.1021/acsomega.2c07718 |
work_keys_str_mv | AT hassannazia insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT farooquzma insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT dasayankumar insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT sharmakalicharan insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT mirzamohdaamir insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT fatimasuhail insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT singhomana insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT ansarimohammadjaved insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT aliasgar insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis AT iqbalzeenat insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis |